MRNA Stock Price, Chart, Stats & News

MRNA chart
Fundamentals
Gross margin | 14.10% |
Operating margin | -158.21% |
Pretax margin | -142.46% |
Net margin | -145.24% |
Effective tax rate | -1.95% |
ROA | -22.87% |
ROE | -30.15% |
D/E | 0.22x |
Interest coverage ratio | -1537.00x |
MRNA valuation
P/E | – |
P/S | 10.07x |
P/B | 2.25x |
P/CF | -10.49x |
P/FCF | -9.53x |
P/OCF | -10.49x |
PEG | -0.69x |
EV multiple | -7.94x |
About
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.
Similar securities
Based on sector and market capitalization











